Gene and Cell Therapy Group
- Public Engagement
- Our research programme
- Jobs and Studentships
- Our research in the media
- Contact Us
- Find Us
Phase I trial to determine the safety of transplanting stem cell-derived retinal cells
Phase I trial to determine the safety of transplanting stem cell-derived retinal cells for people with Stargardt Macular Degeneration
The cells being injected are retinal pigment epithelium (RPE) cells that were grown from human embryonic stem cells in a dish, by the American company Advanced Cell Technology Inc.
This trial involves patients who are already severely visually impaired and is designed to show whether the injection of these cells is safe - future studies will be required to determine if cell transplantation can restore sight.
- Cell transplantation and stem cell therapy for sight loss
- Visit the EyeTherapy information hub for more details on the clinical trial of stem cell-derived retinal cells in Stargardt disease and how we are developing cell transplantation for sight loss.
- The Guardian: Stem cell scientists take hope from first human trials but see long road ahead
Page last modified on 07 jul 15 13:38